Bioventus entered into a collaboration agreement with MTF Biologics to co-develop a next-generation placental tissue product to treat musculoskeletal conditions, initially focusing on knee osteoarthritis.
“We also expect to work together to develop additional uses and indications for this product as part of this program,” said Tony Bihl, CEO, Bioventus. “There is a promising and growing body of preclinical and clinical evidence underscoring the potential of these preparations in supporting the body’s natural healing processes thanks to the inherent growth factors and regulatory molecules present in placental tissues.”
Bioventus entered into a collaboration agreement with MTF Biologics to co-develop a next-generation placental tissue product to treat musculoskeletal conditions, initially focusing on knee osteoarthritis.
“We also expect to work together to develop additional uses and indications for this product as part of this...
Bioventus entered into a collaboration agreement with MTF Biologics to co-develop a next-generation placental tissue product to treat musculoskeletal conditions, initially focusing on knee osteoarthritis.
“We also expect to work together to develop additional uses and indications for this product as part of this program,” said Tony Bihl, CEO, Bioventus. “There is a promising and growing body of preclinical and clinical evidence underscoring the potential of these preparations in supporting the body’s natural healing processes thanks to the inherent growth factors and regulatory molecules present in placental tissues.”
Copy to clipboard 
